Breaking News

FORMA Names Medicinal, CompChemistry VP

By Kristin Brooks | January 7, 2014

Dinsmore brings extensive discovery and development expertise

Christopher Dinsmore, Ph.D., has been appointed vice president of Medicinal and Computational Chemistry at FORMA Therapeutics. Dr. Dinsmore joins the company after 19 years with Merck & Co., where he helped build the Merck Research Lab in Boston.
 
Dr. Dinsmore most recently served as executive director of Discovery Chemistry at Merck, where he led the discovery and advancement of seven compounds in clinical development, as well as several additional preclinical candidates. He has held various scientific and managerial leadership positions including membership in strategic committees managing external research partnerships and oncology in-licensing opportunities. 
 
“Chris is an experienced chemist and team leader with a broad background in the identification and development of therapeutics for oncology and cardiovascular diseases, Alzheimer's, asthma and rheumatoid arthritis,” said Kenneth W. Bair, Ph.D., chief scientific officer and head of R&D at FORMA Therapeutics. “As a founding member of Merck’s Boston site, he helped build highly integrated and collaborative new approaches to discovery research, which is precisely what FORMA strives to accomplish.”
 
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.